Danuglipron
Overview
Danuglipron is an oral, non-peptide small-molecule agonist of the GLP-1 receptor developed to provide convenient daily dosing for type 2 diabetes and obesity. It mimics the effects of endogenous GLP-1 by enhancing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. The small-molecule structure enables oral bioavailability without the need for injection.
Key Research Findings
Phase 2 studies in type 2 diabetes showed dose-dependent reductions in HbA1c and body weight, with data presented at diabetes conferences in 2022 and 2023. Gastrointestinal tolerability challenges were noted, prompting evaluation of modified dosing regimens. Further clinical development is ongoing to optimize therapeutic benefit and adherence.
Oral
In Clinical Trials
Interested in Danuglipron?
Find a verified provider experienced with Danuglipron protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Danuglipron ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.